



# PHARMA MONTHLY

JUNE 2026

**PROGRESSIVE**<sup>®</sup>  
Your Progress Our Priority...



## Key News for the Month

### Company

- FDA approval puts Wockhardt's Zaynich in USD9bn antibiotics market
- Alkem rolls out single-shot semaglutide syringes at Rs350 for diabetes, weight loss
- Delhi HC allows Intas to sell cancer drug Bevatias, sets aside order favouring Sun Pharma
- Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns
- Granules Pharmaceuticals, Inc. receives USFDA EIR for Chantilly facility
- Zydus Lifesciences has received a warning letter from the USFDA for its formulation manufacturing facility at Baddi, Himachal Pradesh
- Aurobindo Pharma enters biologics contract manufacturing with Rs1,200cr Telangana facility
- Maharashtra FDA seizes FDC Enerzal stock over misbranding allegations
- Aurobindo Pharma receives USFDA final approval for Tofacitinib Tablets, 5/10mg
- Alembic Pharma executed a shareholders' agreement for a 45% stake in Canadian Corporation
- SBI in USD1bn funding for Sun Pharma's US deal
- Alembic Pharmaceuticals receives USFDA tentative approval for Larotrectinib capsules, 25/100mg
- Glenmark launches Winlevi (clascoterone) 10mg/g cream in key EU markets
- Dr. Reddy's announces the first-to-market launch of Bosutinib tablets 400mg in the US
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriers
- Novartis India launches Pluvicto for prostate cancer treatment
- Zydus Lifesciences completes acquisition of Assertio
- Alembic Pharma gets USFDA nod for generic influenza treatment drug
- Lupin gets USFDA tentative approval for prostate cancer treatment drug
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soon
- Eugia Steriles (wholly owned step-down subsidiary of Aurobindo) facility ended with 5 observations
- Sun Pharma adds Innovcare to its fold in Rs271.2cr all-cash transaction
- Zydus, Sunshine to set up USD20mn pharma JV in Sri Lanka
- Strides Pharma sells majority stake in arm Pivot Path for Rs100cr
- Alkem Medtech (WoS) has executed its first supplementary agreement to share purchase agreement dt: 06th Mar'26 with inter alia the selling shareholders of Occlutech

### Industry

- Pharma exports to US seen muted this year
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supply
- India's anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
- Indian cancer patients battle shortage of key drugs as platinum costs surge

### Global

- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- Alzecure enters collaboration and with Lilly for Alzheimer's project
- Puerto Rico makes its case as a biotech manufacturing hub
- Roche takes aim at Illumina's dominance with new gene sequencing machine

## Tentative ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Alembic Pharma</b>	Larotrectinib Capsules	25/100mg	Indicated for the treatment of adult and pediatric patients with solid tumors	Vitrakvi Capsules (Bayer Healthcare Pharmaceuticals Inc.)	USD91mn
<b>Alembic Pharma</b>	Binimetinib Tablets	45mg	Indicated for the treatment of patients with unresectable or metastatic melanoma	Mektovi Tablets (Array)	USD259mn
<b>Lupin</b>	Enzalutamide Tablets	40/80/120/160mg	Used to treat various types of advanced prostate cancer	Xtandi(Astellas)	-

Source: Media Reports and Company Press Releases

## Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
<b>Natco Pharma</b>	Eribulin Mesylate Injection	1mg/2ml (0.5mg/ml) Single-Dose Vials	Indicated for the treatment of adults with metastatic breast cancer	Halaven (Eisai, Inc.)	USD43.7mn (annual sales Apr'26)
<b>Lupin</b>	Ranluspec	0.3mg (0.05mL of 6mg/mL), and 0.5mg (0.05mL of 10mg/mL)	Indicated for the treatment of patients with neovascular (wet) age-related macular degeneration	Lucentis (Genentech)	-
<b>Glenmark Pharma</b>	Lacosamide Injection	200mg/20mL (10mg/mL), single-dose vials	Indicated to treat partial-onset seizures	Vimpat (UCB Inc.)	USD15.2mn (annual sales Apr'26)
<b>Alembic Pharma</b>	Haloperidol Tablets	1/2/5/10/20mg	Used in the management of manifestations of psychotic disorders	Haldol Tablets (Ortho McNeil Pharmaceutical)	USD27mn (annual sales Mar'26)
<b>Alembic Pharma</b>	Tretinoin Cream	0.05%	Indicated for topical application in the treatment of acne vulgaris	Retin-A Cream (Bausch Health US, LLC)	USD76mn
<b>Alembic Pharma</b>	Dapsone Gel	5%	Indicated for the topical treatment of acne vulgaris	Aczone Gel (Almirall, LLC)	-
<b>Alembic Pharma</b>	Oseltamivir Phosphate for Oral Suspension	6mg/mL	Indicated for treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older	Tamiflu Oral Suspension (Hoffmann-La Roche, Inc.)	USD27mn

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
3B BlackBio Dx Ltd	1169	5.7%	-17.9%	-19.6%
Aarti Drugs Ltd	378	-1.2%	-7.6%	-17.6%
Aarti Pharmed Labs Ltd	681	6.0%	-9.0%	-23.7%
Abbott India Ltd	25437	-5.0%	-10.8%	-28.6%
Acutaas Chemicals Ltd	3526	16.9%	113.1%	206.0%
Advanced Enzyme Technologies Ltd	308	-18.9%	2.7%	-4.1%
Ajanta Pharma Ltd	3423	16.6%	25.6%	33.0%
Akums Drugs and Pharmaceutical Ltd	623	18.9%	38.1%	6.6%
Alembic Pharmaceuticals Ltd	824	14.6%	-1.5%	-21.0%
Alivus Lifesciences Ltd	1156	10.3%	28.5%	14.2%
Alkem Laboratories Ltd	5571	4.8%	2.8%	13.0%
Anuh Pharma Ltd	81	5.7%	1.4%	-62.4%
Apollo Hospitals Enterprise Ltd	8688	7.3%	24.3%	20.0%
Artemis Medicare Services Ltd	265	-1.0%	-0.8%	5.1%
Aster DM Healthcare Ltd	785	8.8%	28.3%	31.7%
AstraZeneca Pharma India	8216	-5.8%	-7.7%	-7.4%
Aurobindo Pharma Ltd	1576	10.0%	32.7%	38.8%
Bajaj Healthcare Ltd	351	19.1%	-15.2%	-30.5%
Biocon Ltd	418	-1.67%	7.2%	17.7%
Bliss GVS Pharma Ltd	540	34.3%	232.3%	241.4%
Blue Jet Healthcare Ltd	525	17.5%	0.9%	-40.1%
Caplin Point Laboratories Ltd	2624	31.4%	46.82%	24.0%
Cipla Ltd	1465	5.3%	-1.8%	-2.7%
Cohance Lifesciences Ltd	455	6.0%	-14.1%	-53.2%
Concord Biotech Ltd	1278	20.5%	-5.6%	-30.3%
Dishman Carbogen Amics Ltd	175	-11.0%	-27.8%	-30.7%
Divi's Laboratories Ltd	6578	0.4%	2.4%	-3.4%
Dr. Agarwal's Health Care Ltd	479	-0.3%	-5.3%	18.7%
Dr. Lal PathLabs Ltd	1647	4.4%	13.1%	-41.0%
Dr. Agarwals Eye Hospital Ltd	5100	-0.01%	-5.0%	12.8%

Source: BSE website; All prices are as on 30th June, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Dr. Reddy's Laboratories Ltd	1357	5.2%	7.2%	5.7%
Emcure Pharmaceuticals Ltd	1836	7.7%	30.9%	41.2%
Eris Lifesciences Ltd	1435	4.0%	-4.7%	-14.6%
FDC Ltd	423	6.7%	3.3%	-13.1%
Fermenta Biotech Ltd	355	18.1%	1.5%	5.6%
Fischer Medical Ventures Ltd	42	15.4%	0.6%	-95.3%
Fortis Healthcare Ltd	957	3.1%	8.9%	20.5%
Gland Pharma Ltd	2483	8.3%	48.0%	35.5%
GSK Pharmaceuticals Ltd	2451	11.2%	2.6%	-27.6%
Glenmark Pharmaceuticals Ltd	2205	0.2%	8.6%	25.8%
Global Health Ltd	1315	12.5%	13.7%	15.4%
GPT Healthcare Ltd	148	3.9%	5.7%	2.5%
Granules India Ltd	813	4.3%	35.9%	64.3%
Gulfic Biosciences Ltd	407	17.1%	21.8%	11.8%
Gujarat Themis Biosyn Ltd	397	0.2%	-8.8%	14.2%
HealthCare Global Enterprises Ltd	631	-2.6%	-5.2%	13.1%
Hester Biosciences Ltd	2161	7.4%	37.1%	16.8%
Hikal Ltd	221	15.3%	-2.8%	-38.4%
Indegene Ltd	526	3.2%	1.2%	-8.7%
Indoco Remedies Ltd	239	13.6%	3.6%	-24.4%
Indraprastha Medical Corp. Ltd	387	3.4%	-12.5%	-20.4%
Innova Captab Ltd	977	13.57%	35.5%	13.8%
IOL Chemicals and Pharma Ltd	145	15.3%	81.2%	49.0%
IPCA Laboratories Ltd	1702	13.9%	22.7%	22.6%
J.B.Chemicals & Pharmaceuticals Ltd	2295	7.2%	27.6%	36.6%
Jagsonpal Pharmaceuticals Ltd	237	17.6%	23.0%	5.8%
Jubilant Pharmova Sciences Ltd	972	-2.0%	-7.2%	-19.6%
Jupiter Life Line Hospitals Ltd	1422	9.3%	1.4%	-5.5%
KMC Speciality Hospitals Ltd	137	19.3%	79.0%	116.5%
Kopran Ltd	190	-3.1%	26.3%	0.8%

Source: BSE website; All prices are as on 30th June, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Kovai Medical Center & Hospital Ltd	5998	11.6%	4.0%	2.6%
KIMS Ltd	814	8.0%	35.1%	21.2%
Krsnaa Diagnostics Ltd	544	0.5%	-23.3%	-22.9%
Kwality Pharmaceuticals Ltd	2802	26.3%	153.7%	164.2%
Laurus Labs Ltd	1518	9.3%	39.1%	109.4%
Laxmi Dental Ltd	225	-2.0%	-16.5%	-48.2%
Lincoln Pharmaceuticals Ltd	624	2.0%	30.6%	10.3%
Lupin Ltd	2420	7.0%	16.3%	24.9%
Mankind Pharma Ltd	2547	9.7%	17.2%	9.6%
Marksans Pharma Ltd	272	14.1%	51.3%	4.0%
Max Healthcare Institute Ltd	1129	20.3%	8.4%	-11.4%
Metropolis Healthcare Ltd	540	-0.2%	16.9%	26.7%
Morepen Laboratories Ltd	59	27.0%	46.3%	-4.3%
Narayana Hrudayalaya Ltd	1971	3.5%	7.7%	-9.2%
Natco Pharma Ltd	932	-0.1%	3.9%	0.5%
Nectar Lifesciences Ltd	12	-4.6%	-37.3%	-47.6%
Neuland Laboratories Ltd	18630	8.4%	24.6%	55.2%
Novartis India Ltd	1435	-5.8%	83.9%	36.4%
Onesource Specialty Pharma Ltd	1652	-10.0%	-6.0%	-24.6%
Orchid Pharma Ltd	975	25.5%	29.6%	36.7%
Panacea Biotec Ltd	567	42.2%	45.9%	32.9%
Pfizer (India) Ltd	4441	-1.5%	-9.9%	-21.8%
Piramal Pharma Ltd	168	-1.6%	-1.8%	-17.3%
Poly Medicare Ltd	1688	26.4%	-0.6%	-23.9%
Procter & Gamble Health Ltd	6328	5.0%	11.9%	7.6%
Rainbow Children's Medicare Ltd	1413	3.5%	7.4%	-9.6%
RPG Life Sciences Ltd	2305	6.3%	0.7%	-7.1%
Sai Life Sciences Ltd	1235	7.9%	35.1%	59.6%
Sanofi Consumer Healthcare India Ltd	4603	0.4%	4.4%	-19.2%
Sanofi India Ltd	3406	9.2%	-16.1%	-46.6%


Source: BSE website; All prices are as on 30th June, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Sastasundar Ventures Ltd	304	1.0%	1.9%	2.4%
Senores Pharmaceuticals Ltd	1330	24.6%	61.8%	127.7%
Sequent Scientific Ltd	277	10.5%	34.2%	43.5%
Shalby Ltd	176	3.9%	-10.2%	-5.3%
Shilpa Medicare Ltd	599	19.9%	89.5%	35.7%
Shree Ganesh Remedies Ltd	635	-2.3%	39.6%	6.0%
Sigachi Industries Ltd	24	7.1%	-25.7%	-51.0%
SMS Pharmaceuticals Ltd	413	14.8%	31.9%	64.8%
Solara Active Pharma Sciences Ltd	577	5.3%	4.5%	-9.0%
Strides Pharma Science Ltd	1093	-0.1%	20.2%	21.6%
SPARC Ltd	235	19.5%	74.5%	44.6%
Sun Pharmaceutical Industries Ltd	1863	3.7%	8.3%	11.1%
Supriya Lifescience Ltd	1017	-3.0%	38.4%	43.3%
Suraksha Diagnostic Ltd	272	-3.2%	2.20%	-16.8%
Suven Life Sciences Ltd	281	2.2%	67.7%	14.7%
Snycom Formulations (India) Ltd	14	-3.6%	1.1%	-26.0%
Syngene International Ltd	440	-1.9%	-31.7%	-31.2%
Tarsons Products Ltd	268	28.5%	14.8%	-32.2%
Themis Medicare Ltd	109	3.8%	9.8%	-16.0%
Thyrocare Technologies Ltd	550	5.3%	21.6%	66.8%
Torrent Pharmaceuticals Ltd	4623	6.3%	21.0%	35.6%
Unichem Laboratories Ltd	464	35.5%	7.6%	-21.3%
Vijaya Diagnostic Centre Ltd	1355	9.6%	29.1%	37.6%
Vimta Labs Ltd	588	26.7%	-1.6%	30.8%
Wanbury Ltd	281	5.7%	22.0%	0.3%
Windlas Biotech Ltd	858	5.3%	11.3%	-4.0%
Wockhardt Ltd	1942	-9.8%	40.9%	13.4%
Yatharth Hospital & Trauma Care Services Ltd	858	8.2%	26.5%	60.1%
Zyodus Lifesciences Ltd	1112	2.0%	23.4%	12.4%

Source: BSE website; All prices are as on 30th June, 2026

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1M	6M	12M
Abbott India Ltd	25437	540513	-5.0%	-10.8%	-28.6%
Alkem Laboratories Ltd	5571	666097	4.8%	2.8%	13.0%
Aurobindo Pharma Ltd	1576	915256	10.0%	32.7%	38.8%
Ajanta Pharma Ltd	3423	427617	16.6%	25.6%	33.0%
Biocon Ltd	418	678188	-1.7%	7.2%	17.7%
Cipla Ltd	1465	1183523	5.3%	-1.8%	-2.7%
Divi's Laboratories Ltd	6578	1746186	0.4%	2.4%	-3.4%
Dr. Reddy's Laboratories Ltd	1357	1132504	5.2%	7.2%	5.7%
Gland Pharma Ltd	2483	409164	8.3%	48.0%	35.5%
Glenmark Pharmaceuticals Ltd	2205	622225	0.2%	8.6%	25.8%
Ipca Laboratories Ltd	1702	431868	13.9%	22.7%	22.6%
J.B. Chemicals & Pharmaceuticals Ltd	2295	368546	7.2%	27.6%	36.6%
Laurus Labs Ltd	1518	819367	9.3%	39.1%	109.4%
Lupin Ltd	2420	1106442	7.1%	16.3%	24.9%
Piramal Pharma Ltd	168	223580	-1.6%	-1.8%	-17.3%
Mankind Pharma Ltd	2290	945398	9.7%	17.2%	9.6%
Sun Pharmaceutical Industries Ltd	1863	4469241	3.7%	8.32%	11.1%
Torrent Pharmaceuticals Ltd	4623	1564498	6.3%	21.0%	35.6%
Wockhardt Ltd	1942	315560	-9.8%	40.9%	13.4%
Zydus Lifesciences Ltd	1112	1119133	2.0%	23.4%	12.4%

Source: NSE website, Company Research; All prices are as on 30th June, 2026



Source: NSE website

## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

## Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai-400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500

### Compliance Officer:

Ms. Mamatha Poojari,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500

### Grievance Officer:

Email: grievancecell@progressiveshares.com